Core Insights - AngioDynamics, Inc. reported its financial results for the second quarter of fiscal year 2026, which ended on November 30, 2025, highlighting its focus on medical technology aimed at improving vascular health and cancer treatment options [1]. Financial Performance - The company achieved net sales of $... for the second quarter, indicating a pro forma year-over-year growth [1].

Core Viewpoint - U.S. stock futures are trading higher, with several companies expected to report earnings and revenue figures that may attract investor attention [1] Company Summaries - **AngioDynamics, Inc. (NASDAQ:ANGO)**: Expected to report a quarterly loss of $0.10 per share on revenue of $76.30 million. Shares decreased by 0.2% to $13.20 in after-hours trading [1] - **Microchip Technology Inc (NASDAQ:MCHP)**: Anticipates third-quarter fiscal 2026 net sales of approximately $1.185 billion, exceeding previous guidance of $1.109 billion to $1.149 billion. Shares increased by 3.2% to $69.20 in after-hours trading [1] - **AAR Corp (NYSE:AIR)**: Analysts expect quarterly earnings of $1.04 per share on revenue of $761.13 million, with earnings to be released after market close. Shares rose by 0.8% to $88.70 in after-hours trading [1] - **Galapagos NV – ADR (NASDAQ:GLPG)**: The board has decided to wind down the company's cell therapy activities after a strategic review. Shares increased by 6% to $34.70 in after-hours trading [1] - **Penguin Solutions Inc. (NASDAQ:PENG)**: Expected to report quarterly earnings of $0.44 per share on revenue of $338.76 million after market close. Shares rose by 0.6% to $21.19 in after-hours trading [1]

Market Sentiment - The CNN Money Fear and Greed index showed improvement in overall market sentiment, remaining in the "Neutral" zone with a current reading of 46.8, up from 44.7 [5] - U.S. stocks experienced a positive session, with the Dow Jones index gaining almost 600 points, reaching a new all-time high [1][3] Stock Performance - In 2025, the S&P 500 surged 16.39%, marking its third consecutive year of double-digit growth, while the Nasdaq Composite increased by 20.36% and the Dow added 12.97% [2] - On Monday, the Dow Jones closed higher by approximately 595 points at 48,977.18, the S&P 500 gained 0.64% to 6,902.05, and the Nasdaq Composite rose 0.69% to 23,395.82 [3] Sector Performance - Most sectors on the S&P 500 closed positively, with energy, financial, and consumer discretionary materials stocks showing the largest gains, while consumer staples and utilities stocks closed lower [3] Upcoming Earnings - Investors are anticipating earnings results from AngioDynamics, Inc. (NASDAQ:ANGO), AAR Corp (NYSE:AIR), and Penguin Solutions Inc (NASDAQ:PENG) [4]

Core Viewpoint - AngioDynamics, Inc. is expected to report a quarterly loss of 10 cents per share for Q2 FY26, which is a decline from a loss of 4 cents per share in the same quarter last year, while revenue is projected to increase to $76.43 million from $72.84 million year-over-year [1] Group 1: Earnings Expectations - The company will release its Q2 earnings results on January 6, 2026, before the market opens [1] - Analysts anticipate a quarterly loss of 10 cents per share, compared to a loss of 4 cents per share in the previous year [1] - The consensus estimate for quarterly revenue is $76.43 million, up from $72.84 million a year earlier [1] Group 2: Stock Performance - AngioDynamics shares fell by 1.8% to close at $12.87 on the previous Friday [2] Group 3: Analyst Ratings - Canaccord Genuity analyst William Plovanic maintained a Buy rating and raised the price target from $17 to $18 on October 3, 2025 [3] - HC Wainwright & Co. analyst Yi Chen also maintained a Buy rating with a price target of $16 on July 16, 2025 [3] - The accuracy rates for these analysts are 62% and 66%, respectively [3]

Core Viewpoint - AngioDynamics, Inc. is expected to report a quarterly loss of 10 cents per share for Q2 FY26, which is a decline from a loss of 4 cents per share in the same quarter last year, while revenue is projected to increase to $76.43 million from $72.84 million year-over-year [1] Group 1: Earnings Expectations - The company will release its Q2 earnings results on January 6, 2026, before the market opens [1] - Analysts anticipate a quarterly loss of 10 cents per share, compared to a loss of 4 cents per share in the previous year [1] - The consensus estimate for quarterly revenue is $76.43 million, an increase from $72.84 million a year earlier [1] Group 2: Stock Performance - AngioDynamics shares fell by 1.8% to close at $12.87 on the previous Friday [2] Group 3: Analyst Ratings - Canaccord Genuity analyst William Plovanic maintained a Buy rating and raised the price target from $17 to $18 on October 3, 2025, with an accuracy rate of 62% [3] - HC Wainwright & Co. analyst Yi Chen also maintained a Buy rating with a price target of $16 on July 16, 2025, achieving an accuracy rate of 66% [3]

Core Insights - AngioDynamics (ANGO) is showing improved execution in the market despite not receiving full recognition [1] - The Medical Tech segment is driving solid growth for the company, indicating a focus on faster-growing areas [1] Company Performance - AngioDynamics continues to make progress, albeit slowly, which is still considered positive [1] - The company is experiencing growth in its Medical Tech segment, which is a key driver of its performance [1]

Group 1 - The core viewpoint is that AngioDynamics (ANGO) is making slow but steady progress, with improved execution in the market despite not receiving full recognition [1] - The Medical Tech segment is identified as the key driver of solid growth for the company, indicating a focus on faster-growing areas within the industry [1]

Core Insights - AngioDynamics is undergoing a significant transformation to shift from a traditional device manufacturer to a focused MedTech company targeting large addressable markets with high gross margins [2][3] Company Overview - AngioDynamics operates on a unique fiscal year that begins on June 1, with the second quarter of FY 2026 nearing completion in three weeks [2] - The company has spent the last five years restructuring its portfolio to enhance competitiveness and focus on areas where it can achieve success [2][3]

Summary of AngioDynamics Conference Call Company Overview - **Company**: AngioDynamics (NasdaqGS: ANGO) - **Fiscal Year**: The company operates on a unique fiscal year starting June 1, currently nearing the end of Q2 for FY 2026 - **Transformation**: AngioDynamics is undergoing a transformation from a diversified medical device company to a focused MedTech company targeting large addressable markets with high gross margins [4][6][8] Key Points on Transformation and Financial Performance - **Revenue Shift**: The MedTech business has grown from less than 17% of total revenue to approximately 45%, with expectations to surpass 50% soon [8][10] - **EBITDA Positive**: The company achieved adjusted EBITDA positivity last fiscal year and expects to maintain this going forward [8][10] - **Cash Flow**: AngioDynamics anticipates being cash flow positive for the fiscal year ending May 31 [9][10] - **Growth Rate**: The MedTech segment has experienced a compound annual growth rate (CAGR) of about 25% over the last five years [12] MedTech Business Insights - **Market Focus**: The MedTech portfolio includes two cardiovascular areas and one interventional oncology area, with significant growth potential in each [14][15] - **Key Products**: - **NanoKnife**: Recently approved for treating intermediate-risk prostate cancer, with a market potential of over $2 billion globally [14][15][75] - **Arion System**: Launched in 2020, it has grown to over $60 million in revenue, focusing on peripheral arterial disease (PAD) [6][43] - **AlphaVac System**: Competing in the venous thromboembolism (VTE) market, showing a 40% growth in Q1 [20][21] Market Dynamics and Growth Drivers - **Interventional Oncology**: The NanoKnife product addresses a significant market need, with a focus on preserving quality of life for patients [78][80] - **Cardiovascular Market**: The company is expanding into coronary interventions, which represent a larger market opportunity [15][46] - **VTE Market**: The mechanical thrombectomy market is expected to grow, with AngioDynamics taking market share from competitors [20][23] Challenges and Opportunities - **Macro Environment**: The healthcare sector faces pressures from Medicare and Medicaid changes, but AngioDynamics believes its product mix positions it well to navigate these challenges [17][18] - **Clinical Evidence**: Ongoing studies and clinical data generation are crucial for market adoption and confidence in mechanical thrombectomy and other products [25][41][58] Financial Outlook - **Sales Growth Guidance**: For FY 2026, AngioDynamics projects overall sales growth of 5-7%, with double-digit growth expected in the MedTech segment [94][98] - **Capital Allocation**: The company plans to focus on innovation within its existing MedTech business rather than pursuing external M&A in the near term [91][93] Conclusion - AngioDynamics is strategically positioned for growth in the MedTech sector, with a strong focus on innovation, clinical evidence, and market expansion. The company is optimistic about its financial trajectory and the potential for its products to capture significant market share in the coming years [84][88][90]

Core Insights - AngioDynamics, Inc. will participate in the UBS Global Healthcare Conference on November 10, 2025, with CEO Jim Clemmer and CFO Stephen Trowbridge presenting [1] - The company's NanoKnife System has been recognized as one of TIME's 2025 Best Inventions, highlighting its innovative impact in medical technology [6] - AngioDynamics reported a net sales figure of $75.7 million for the first quarter of fiscal year 2026, reflecting a year-over-year growth of 26.1% in the medical technology sector [7] Company Overview - AngioDynamics is a medical technology company focused on restoring healthy blood flow, expanding cancer treatment options, and improving patient quality of life [3][6] - The company’s innovative technologies are utilized by physicians in rapidly growing healthcare markets to address unmet patient needs [3] Financial Performance - For the first quarter of fiscal year 2026, which ended on August 31, 2025, AngioDynamics achieved net sales of $75.7 million, indicating strong growth in the medical technology sector [7]